Perspective Therapeutics, Inc. quarterly report, Q1 FY2024

Perspective Therapeutics, Inc. — Q1 2024 Form 10-Q

Reporting period: Three months ended March 31, 2024. The company is developing precision-targeted alpha therapies for cancer and has no product sales from its drug-development business. Following the April 12, 2024 sale of its Cesium-131 brachytherapy business, it plans to focus exclusively on radiopharmaceutical development.

Financial results and liquidity

Metric	Q1 2024	Q1 2023
Grant revenue	$0.325 million	$0.233 million
Research and development expense	$7.452 million	$3.309 million
General and administrative expense	$5.878 million	$6.663 million
Operating loss	$13.005 million	$9.761 million
Net loss	$12.284 million	$0.371 million
Net cash from (used in) operating activities	$13.848 million	($9.723 million)

• Grant revenue rose about 39%, while R&D expense more than doubled, reflecting increased development costs for the Viewpoint-derived programs. G&A declined about 12%, partly because Q1 2023 included merger expenses.
• The Q1 2023 net loss benefited from a $10.5 million deferred tax benefit; Q1 2024 recorded no such benefit. Continuing-operations net loss was $11.825 million versus $9.405 million.
• There is no meaningful product-sales margin for the continuing drug-development business. The discontinued brachytherapy business reported $1.973 million in sales, $0.571 million gross profit and a $0.461 million net loss in Q1 2024.
• At March 31, cash and cash equivalents were $142.1 million and short-term investments were $38.5 million, totaling $180.6 million. Current assets were $188.2 million against current liabilities of $14.5 million.
• Operating cash flow was positive primarily because of the $28.0 million Lantheus option-agreement payment, classified as deferred income; it should not be viewed as a recurring operating cash source. The company used $9.1 million for property and equipment and $38.2 million to purchase short-term investments.
• Financing activities provided $166.3 million, principally from equity transactions. Total liabilities were $48.4 million, including $1.7 million of notes payable and $1.2 million of lease liabilities. The $28.0 million deferred-income balance relates to the Lantheus options, not conventional borrowing.

Material changes and transactions

• Common shares outstanding increased from 281.8 million at December 31, 2023 to 586.9 million at March 31, 2024, following the January public offering, Lantheus investment and March private placement. The company reported 622.6 million shares outstanding as of May 10, 2024.
• Q1 equity financings generated approximately $177.2 million gross: about $69.0 million from the January public offering, $20.0 million from Lantheus and $87.4 million from the March private placement. In addition, the company sold shares through its ATM program on April 11 for approximately $49.5 million gross.
• Lantheus paid $28.0 million for options relating to the [212Pb]VMT-α-NET program and certain early-stage candidates. The agreement does not require the company to license or sell the programs; the related deferred income is expected to be recognized as the options expire.
• The company acquired a radiopharmaceutical manufacturing facility in Somerset, New Jersey, for $8.0 million and recognized a lease liability and right-of-use asset. It also acquired an exclusive in-license to Stony Brook University’s CB7-Adma pre-targeting platform.
• The April 12 brachytherapy divestiture consideration included 279,516 shares of GT Medical, representing 0.5% ownership at closing, plus potential royalties over four years based on sales. The financial statements present the business as discontinued operations.

Outlook, clinical progress and risks

• Management believes March 31 cash and short-term investments will fund planned operations into Q1 2026. That estimate depends on assumptions; management expects spending, particularly R&D, to increase in 2024 and beyond. The filing does not provide an updated runway estimate incorporating the April ATM proceeds.
• The principal clinical programs, [212Pb]VMT-α-NET for neuroendocrine tumors and [212Pb]VMT01 for metastatic melanoma, are in Phase 1/2a studies. The company reported beginning Cohort 2 dosing and, as of March 31, no unexpected adverse events for VMT01. It announced a Bristol Myers Squibb collaboration to evaluate VMT01 with nivolumab.
• FDA selected VMT-α-NET for its CMC Development and Readiness Pilot Program. The company also expects to expand manufacturing capacity for clinical supply and potential future demand; successful facility conversion and scale-up are not assured.
• The company has recurring losses and expects to need additional capital before profitability, which may never occur. Additional equity financing could dilute shareholders; other funding or licensing arrangements could limit rights. Clinical, regulatory, manufacturing, enrollment and commercialization outcomes remain uncertain.
• The filing reports an estimated liability of up to $0.2 million for settlement negotiations concerning claims related to a 2022 proxy statement. Management reported no material changes to previously disclosed risk factors and no off-balance-sheet arrangements.

Important facts for investors to verify

• Whether the stated cash runway remains consistent with rising trial, R&D and manufacturing costs, including the effect of post-quarter ATM financing.
• Clinical-trial enrollment, safety and efficacy updates for VMT-α-NET and VMT01, and milestones or obligations under the Lantheus and Bristol Myers Squibb agreements.
• Actual dilution from the large Q1 financings, outstanding pre-funded warrants and options, and subsequent share issuance.
• Progress, costs and operational readiness of the Somerset manufacturing facility.
• Realized value of the GT Medical shares and any royalties, which depend on future sales and are not assured.